SCHEMBL4464500

SCHEMBL4464500

CCc1c(OC(C)=O)c(C(C)C)cc2c1C(=O)CC1(CCC1)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.38
ALDH1A1 P00352 13/20 0.38
HPGD P15428 9/20 0.38
KMT2A Q03164 3/20 0.35
ATM Q13315 2/20 0.35
HTT P42858 1/20 0.35
GAA P10253 7/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HSD17B10 Q99714 6/20 0.34
CASP1 P29466 5/20 0.34
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KLK7 P49862 1/20 0.34
GLA P06280 6/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462456 0.87 KDM4E (0.41) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4470869 0.76 KDM4E (0.35) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4468435 0.75 KDM4E (0.44) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4462461 0.73 KDM4E (0.40) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4511670 0.69 KDM4E (0.37) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4468788 0.67 KMT2A (0.38) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL17762901 0.67 KDM4E (0.42) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4497492 0.66 ALDH1A1 (0.46) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL4473238 0.66 KDM4E (0.43) KDM4EALDH1A1HPGDKMT2AATM
SCHEMBL6764105 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 KDM4E 3310/4885ALDH1A1 169/4885HPGD 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.